Ultragenyx Pharmaceutical Shares Bought by Rafferty Asset Management

Institutional investor increased stake in biopharmaceutical company by 93% in Q3

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Rafferty Asset Management LLC increased its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 93% during the third quarter, according to a recent SEC filing. The institutional investor now owns 156,484 shares of the biopharmaceutical company's stock, worth approximately $4.7 million.

Why it matters

Ultragenyx Pharmaceutical is a rare disease-focused biopharmaceutical company that has seen significant institutional interest and trading activity in recent quarters. This latest move by Rafferty Asset Management highlights the continued investor interest in the company's pipeline and commercial products.

The details

According to the 13F filing, Rafferty Asset Management purchased an additional 75,388 shares of Ultragenyx Pharmaceutical during the third quarter, increasing its total stake by 93%. The firm now owns approximately 0.16% of the company's outstanding shares.

  • Rafferty Asset Management increased its stake in Ultragenyx Pharmaceutical during the third quarter of 2026.

The players

Rafferty Asset Management LLC

An institutional investor and asset management firm.

Ultragenyx Pharmaceutical Inc.

A biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders.

Got photos? Submit your photos here. ›

The takeaway

Ultragenyx Pharmaceutical's continued institutional investor interest highlights the potential of its rare disease-focused pipeline and commercial products, despite recent stock price volatility and legal challenges.